Premature Deaths and Life-Years Lost From Lack of Amivantamab in Brazil's Unified Health System
Delayed SUS incorporation of amivantamab may result in over a 1,000 preventable deaths and life-years lost among Brazilian EGFR exon 20-mutated NSCLC. Urgent real-world studies and cost-effectiveness analyses are needed.
Authors
- Wallace Klein Schwengber (ORCID: https://orcid.org/0000-0001-5955-8170)
- L.S. Lago
- Gabriel Lenz (ORCID: https://orcid.org/0000-0003-3891-525X)
- Gilberto Lopes (ORCID: https://orcid.org/0000-0002-1151-9903)
- Nicolas Peruzzo (ORCID: https://orcid.org/0000-0002-2420-4476)
- Rafael Alvim Pereira (ORCID: https://orcid.org/0009-0000-3968-6618)
- Milena Tumelero (ORCID: https://orcid.org/0009-0000-6999-6019)
Institutions
- Universidade Feevale (BR)
- Georgetown University (US)
- AdventHealth Orlando (US)
- Santa Casa Hospital (BR)
- MedStar Union Memorial Hospital (US)
- Mayo Clinic in Arizona (US)
- Mayo Clinic Hospital (US)
- Universidade do Oeste de Santa Catarina (BR)
- Sylvester Comprehensive Cancer Center (US)
Publication Details
- Journal
- JCO Global Oncology
- Published
- 2025-11-01
- DOI
- https://doi.org/10.1200/go-25-00302
- Primary Topic
- Health Systems, Economic Evaluations, Quality of Life
- Type
- article
- Field-Weighted Citation Impact
- 0.00